Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo

Sidhpura, Nimish; Redfern, P. H.; Rowley, Helen L.; Heal, David J.; Wonnacott, Susan

doi:10.1016/j.bcp.2007.06.025

Cited by 39 publications

(33 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, BP potentiates the behavioral locomotor effects of nicotine, and vice versa, nicotine pretreatment facilitates the locomotion mediated by BP [76] . In this regard, Biała's laboratory measured the locomotor activity of rodents in the testing apparatus for the CPP test [73,74] .…”

Section: Figure 3 Molecular Interaction Of (R)-bp and (S)-sadu-3-72 mentioning

confidence: 94%

Interaction of nicotinic receptors with bupropion: Structural, functional, and pre-clinical perspectives

Arias¹,

Biała²,

Kruk-Słomka³

et al. 2014

Receptor Clin Invest

View full text Add to dashboard Cite

Besides the antidepressant activity of bupropion (BP), preclinical studies in rodents provide evidence that this compound and its hydroxyl metabolites can attenuate nicotine withdrawal, reversing both the physical and negative affective aspects of nicotine abstinence. Co-interactions of BP with nicotine or other psychostimulants influence decrease anxiety-and cognitive-related processes. BP also attenuates the reinstatement of nicotine-induced conditioned place preference in rats caused by a priming dose of nicotine, morphine, cannabinoids, or ethanol.

show abstract

Section: Figure 3 Molecular Interaction Of (R)-bp and (S)-sadu-3-72 mentioning

confidence: 94%

Interaction of nicotinic receptors with bupropion: Structural, functional, and pre-clinical perspectives

Arias¹,

Biała²,

Kruk-Słomka³

et al. 2014

Receptor Clin Invest

View full text Add to dashboard Cite

show abstract

“…It is of interest that in spite of reducing burying behavior, bupropion at 60 mg/kg increased locomotor activity. Indeed, a microdialysis study revealed that bupropion increases dopamine release in the nucleous accumbens, which crucially mediates locomotor activity [9] . It is not clear whether the dopaminergic component of bupropion contributes to the reduction in the number of buried marbles or not.…”

Section: Resultsmentioning

confidence: 99%

Pharmacologically Distinctive Behaviors other than Burying Marbles during the Marble Burying Test in Mice

Kuratani

Kinoshita

Hara³

2010

Pharmacology

View full text Add to dashboard Cite

In the marble burying test, we focused on the 5 distinctive behavioral parameters of mice other than burying marbles, i.e. digging, latency to the first digging, exploration around marbles, rearing and locomotor activity. Typical anxiolytics or antidepressants with different mechanisms, fluvoxamine (30 mg/kg, selective serotonin reuptake inhibitor), bupropion (60 mg/kg, noradrenaline and dopamine reuptake inhibitor), imipramine (60 mg/kg, tricyclic antidepressant) and diazepam (10 mg/kg, benzodiazepine) were used to examine whether these behavioral parameters are sensitive to pharmacological treatments. Each of the drugs demonstrated an individual action pattern on the 4 behavioral parameters (latency to the first digging, exploration around marbles, rearing and locomotor activity). On the other hand, all 4 drugs reduced burying marbles and digging, which were correlated with each other. These results suggest that the former 4 behavioral parameters are sensitive to pharmacological treatment and that pharmacological regulation mechanisms of them may be different from burying marbles and digging. They could be useful to identify the type of action of a test drug like selective serotonin reuptake inhibitor, noradrenaline and dopamine reuptake inhibitor, tricyclic antidepressant or benzodiazepine.

show abstract

“…The antidepressant, bupropion, has demonstrated benefit as a tobacco use cessation agent [141, 142, 175, 197–201]. In addition to its antidepressant activity, which presumably derives from its ability to inhibit DA and NE transport into the presynaptic nerve terminal, bupropion is an effective and well-tolerated tobacco use cessation agent [199, 202].…”

Section: Nachr Antagonists As Smoking Cessation Treatmentsmentioning

confidence: 99%

Nicotinic receptor-based therapeutics and candidates for smoking cessation

Dwoskin

Smith

Wooters

et al. 2009

Biochemical Pharmacology

View full text Add to dashboard Cite

Tobacco dependence is the most preventable cause of death and is a chronic, relapsing disorder in which compulsive tobacco use persists despite known negative health consequences. All currently available cessation agents (nicotine, varenicline and bupropion) have limited efficacy and are associated with high relapse rates, revealing a need for more efficacious, alternative pharmacotherapies. The major alkaloid in tobacco, nicotine, activates nicotinic receptors (nAChRs) which increase brain extracellular dopamine producing nicotine reward leading to addiction. nAChRs are located primarily presynaptically and modulate synaptic activity by regulating neurotransmitter release. Subtype-selective nAChR antagonists that block reward-relevant mesocorticolimbic and nigrostriatal dopamine release induced by nicotine may offer advantages over current therapies. An innovative approach is to provide pharmacotherapies which are antagonists at nAChR subtypes mediating nicotine evoked dopamine release. In addition, providing multiple medications with a wider array of targets and mechanisms should provide more treatment options for individuals who are not responsive to the currently available pharmacotherapies. This review summarizes the currently available smoking cessation therapies and discusses emerging potential therapeutic approaches employing pharmacological agents which act as antagonists at nicotinic receptors.

show abstract

Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo

Cited by 39 publications

References 27 publications

Interaction of nicotinic receptors with bupropion: Structural, functional, and pre-clinical perspectives

Interaction of nicotinic receptors with bupropion: Structural, functional, and pre-clinical perspectives

Pharmacologically Distinctive Behaviors other than Burying Marbles during the Marble Burying Test in Mice

Nicotinic receptor-based therapeutics and candidates for smoking cessation

Contact Info

Product

Resources

About